Retaturtide
$80.00 - $135.00
Retatrutide is an investigational once-weekly "triple agonist" peptide (GIP, GLP-1, and glucagon receptors) developed by Eli Lilly for obesity and diabetes, showing promising phase 3 results of up to 24-30% weight loss in trials. It works by targeting appetite, fat metabolism, and energy expenditure, with side effects similar to GLP-1